NASDAQ: MBOT Microbot Medical Inc. 8-K

Microbot Medical reports first LIBERTY System revenue in Q1, Q2 already exceeds Q1 total

Filed May 14, 2026 · Period ending May 14, 2026 · ~1 min read

Key Changes

high

Company generated first revenue from LIBERTY Endovascular Robotic System during Q1 2026 limited market release, marking commercial launch of flagship product.

Item 7.01 verify on EDGAR →
high

Q2 2026 revenue has already surpassed entire Q1 total following transition to full market release, with accelerating adoption across multiple sales territories.

Item 7.01 verify on EDGAR →

Summary

Microbot Medical disclosed its first commercial revenue from the LIBERTY Endovascular Robotic System, generated during a limited market release in Q1 2026. This marks a critical inflection point for the medical device company, transitioning from development to revenue-generating operations with its flagship robotic surgical product. More significantly, the company revealed that Q2 2026 revenue has already exceeded the entire Q1 total, despite Q2 being incomplete at the time of filing.

This acceleration followed the transition from limited to full market release, with the company citing increased utilization across multiple sales territories. For retail investors, this suggests strong early market acceptance and validates the commercial potential of the LIBERTY System. Key item to watch: the company's Q2 earnings report, which should provide actual revenue figures and guidance on whether this momentum can be sustained as the product scales beyond initial adopters.

Section-by-Section Diff

Event · Item 7.01 — Regulation FD Disclosure

~200 words

Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.

1 Added

Added Q2 2026 revenue exceeding Q1 high

Added in current filing · verify on EDGAR →

the Company’s recent transition to the full market release has resulted in increased revenue for the second quarter of 2026, which has already exceeded Q1 revenue, as utilization and adoption of the LIBERTY System accelerates across multiple sales territories

The company transitioned from limited to full market release of the LIBERTY system and disclosed that Q2 2026 revenue has already surpassed the entire Q1 2026 revenue, indicating accelerating adoption across multiple sales territories. This suggests strong commercial momentum for the product.

Event · Item 8.01 — Other Events

~300 words

Item 8.01 — Other Events filed; see Key Changes for terms.

1 Added

Added Q2 2026 revenue exceeding Q1 high

Added in current filing · verify on EDGAR →

the Company’s recent transition to the full market release has resulted in increased revenue for the second quarter of 2026, which has already exceeded Q1 revenue, as utilization and adoption of the LIBERTY System accelerates across multiple sales territories

The company transitioned from limited to full market release of the LIBERTY System and reports that Q2 2026 revenue has already surpassed the entire Q1 2026 revenue, with accelerating adoption across multiple sales territories. This suggests strong commercial momentum and market acceptance of the product following the broader launch.

Event · Item 9.01 — Financial Statements and Exhibits

~100 words

Microbot Medical filed an 8-K attaching a press release with no material business event disclosed in the filing body.

1 Added

Added Press release attachment medium

Added in current filing · verify on EDGAR →

Exhibit | Number | Description | 99.1 | Press Release

The 8-K attaches a press release as Exhibit 99.1. The filing body provides no details about the press release content, making it impossible to assess materiality without reviewing the actual exhibit.